Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Publication ,  Journal Article
Pili, R; Häggman, M; Stadler, WM; Gingrich, JR; Assikis, VJ; Björk, A; Nordle, O; Forsberg, G; Carducci, MA; Armstrong, AJ
Published in: J Clin Oncol
October 20, 2011

PURPOSE: The activity of the novel antitumor agent tasquinimod (TASQ) with S100A9 as a molecular target was investigated in men with metastatic castration-resistant prostate cancer (CRPC) and minimal symptoms. PATIENTS AND METHODS: We conducted a randomized, double-blind, placebo-controlled phase II trial in men assigned (at a ratio of two to one) to either oral once-daily TASQ 0.25 mg/d escalating to 1.0 mg/d over 4 weeks or placebo. The primary end point was the proportion of patients without disease progression at 6 months, defined by Response Evaluation Criteria in Solid Tumors Group, Prostate Cancer Working Group (PCWG2), or pain criteria, excluding prostate-specific antigen. RESULTS: Two hundred one men (134 assigned to TASQ; 67 to placebo) were evaluable, and baseline characteristics were well balanced. Six-month progression-free proportions for TASQ and placebo groups were 69% and 37%, respectively (P < .001), and median progression-free survival (PFS) was 7.6 versus 3.3 months (P = .0042). In PCWG2 CRPC clinical subgroups, PFS in months was as follows: nodal metastases, 6.1 versus 3.1; bone metastases, 8.8 versus 3.4; and visceral metastases, 6.0 versus 3.0 for patients receiving TASQ versus placebo, respectively. Bone alkaline phosphatase levels were stabilized in the TASQ group, whereas the impact on PSA kinetics was less pronounced. Adverse events (AEs) occurring more frequently in the TASQ arm included GI disorders, fatigue, musculoskeletal pains, and elevations of pancreatic and inflammatory biomarkers. Grade 3 to 4 AEs, including asymptomatic elevations of laboratory parameters, were reported in 40% of patients receiving TASQ versus 10% receiving placebo; deep vein thrombosis (4% v 0%) was more common in the TASQ arm. CONCLUSION: TASQ significantly slowed progression and improved PFS in patients with metastatic CRPC with an acceptable AE profile.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

October 20, 2011

Volume

29

Issue

30

Start / End Page

4022 / 4028

Location

United States

Related Subject Headings

  • Quinolones
  • Quinolines
  • Prostatic Neoplasms
  • Placebos
  • Orchiectomy
  • Oncology & Carcinogenesis
  • Neoplasms, Hormone-Dependent
  • Neoplasm Metastasis
  • Molecular Targeted Therapy
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pili, R., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Björk, A., … Armstrong, A. J. (2011). Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol, 29(30), 4022–4028. https://doi.org/10.1200/JCO.2011.35.6295
Pili, Roberto, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasileios J. Assikis, Anders Björk, Orjan Nordle, Goran Forsberg, Michael A. Carducci, and Andrew J. Armstrong. “Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.J Clin Oncol 29, no. 30 (October 20, 2011): 4022–28. https://doi.org/10.1200/JCO.2011.35.6295.
Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20;29(30):4022–8.
Pili, Roberto, et al. “Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.J Clin Oncol, vol. 29, no. 30, Oct. 2011, pp. 4022–28. Pubmed, doi:10.1200/JCO.2011.35.6295.
Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20;29(30):4022–4028.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

October 20, 2011

Volume

29

Issue

30

Start / End Page

4022 / 4028

Location

United States

Related Subject Headings

  • Quinolones
  • Quinolines
  • Prostatic Neoplasms
  • Placebos
  • Orchiectomy
  • Oncology & Carcinogenesis
  • Neoplasms, Hormone-Dependent
  • Neoplasm Metastasis
  • Molecular Targeted Therapy
  • Middle Aged